HS235, the company’s lead drug candidate, has completed an early stage clinical trial and is set to begin studying the drug’s effects on patients with pulmonary arterial hypertension. The progressive disease is characterised by high blood pressure in the arteries of the lungs, and pulmonary hypertension caused by heart failure.